Ausgewählte Veröffentlichungen

Pharmacological Landscape of FDA-approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas.

Jungwirth G, Yu T, Liu F, Cao J, Eddine MA, Moustafa M, Abdollahi A, Warta R, Unterberg A, Herold-Mende C.

Clin Cancer Res, 2023 Jan 4;29(1):233-243. doi: 10.1158/1078-0432.CCR-22-2085.

Reprogramming M2-polarized patient-derived glioblastoma associated microglia/macrophages via CSF1R inhibition.

Fermi V, Warta R, Rapp C, Knoll M, Jungwirth G, Jungk C, Trong PD, von Deimling A, Abdollahi A, Unterberg A, Herold-Mende C.

bioRxiv, 2022 Oct 21;511747. doi: 10.1101/2022.10.20.511747

Luminescent Pyrrole-Based Phosphaphenalene Gold Complexes: Versatile Anticancer Tools with Wide Applicability.

Fermi V, Regulska E, Wolfram A, Wessling P, Rominger F, Herold-Mende C*, Romero-Nieto C*. *shared last-authorship

Chemistry, 2022 Jun 15;28(34):e202104535. doi: 10.1002/chem.202104535. Epub 2022 Apr 19

KIF11 inhibitors filanesib and ispinesib inhibit meningioma growth in vitro and in vivo.

Jungwirth G, Yu T, Cao J, Eddine MA, Moustafa M, Warta R, Debus J, Unterberg A, Abdollahi A, Herold-Mende C.

Cancer Lett, 2021 May 28;506:1-10. doi: 10.1016/j.canlet.2021.02.016. Epub 2021 Feb 27

Large-Scale Drug Screening in Patient-Derived IDHmut Glioma Stem Cells Identifies Several Efficient Drugs among FDA-Approved Antineoplastic Agents.

Dao Trong P, Jungwirth G, Yu T, Pusch S, Unterberg A, Herold-Mende C, Warta R.

Cells, 2020 Jun 3;9(6):1389. doi: 10.3390/cells9061389.

Surfactant Expression Defines an Inflamed Subtype of Lung Adenocarcinoma Brain Metastases that Correlates with Prolonged Survival.

Pocha K, Mock A, Rapp C, Dettling S, Warta R, Geisenberger C, Jungk C, Martins LR, Grabe N, Reuss D, Debus J, von Deimling A, Abdollahi A, Unterberg A, Herold-Mende C.

Clin Cancer Res, 2020 May 1;26(9):2231-2243. doi: 10.1158/1078-0432.CCR-19-2184. Epub 2020 Jan 17.

Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas.

Rapp C, Dettling S, Liu F, Ull AT, Warta R, Jungk C, Roesch S, Mock A, Sahm F, Schmidt M, Jungwirth G, Zweckberger K, Lamszus K, Gousias K, Kessler AF, Grabe N, Loehr M, Ketter R, Urbschat S, Senft C, Westphal M, Abdollahi A, Debus J, von Deimling A, Unterberg A, Simon M, Herold-Mende C.

Clin Cancer Res, 2019 Sep 1;25(17):5260-5270. doi: 10.1158/1078-0432.CCR-19-0389. Epub 2019 Jun 21.

Impact of post-surgical freezing delay on brain tumor metabolomics.

Mock A, Rapp C, Warta R, Abdollahi A, Jäger D, Sakowitz O, Brors B, von Deimling A, Jungk C, Unterberg A, Herold-Mende C.

Metabolomics, 2019 May 13;15(5):78. doi: 10.1007/s11306-019-1541-2.

MetaboDiff: an R package for differential metabolomic analysis.

Mock A, Warta R, Dettling S, Brors B, Jäger D, Herold-Mende C.

Bioinformatics, 2018 Oct 1;34(19):3417-3418. doi: 10.1093/bioinformatics/bty344.

Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-cell Targets in Human IDH-Mutant Glioma.

Dettling S, Stamova S, Warta R, Schnölzer M, Rapp C, Rathinasamy A, Reuss D, Pocha K, Roesch S, Jungk C, Warnken U, Eckstein V, Grabe N, Schramm C, Weigand MA, von Deimling A, Unterberg A, Beckhove P, Herold-Mende C.

Clin Cancer Res, 2018 Jun 15;24(12):2951-2962. doi: 10.1158/1078-0432.CCR-17-1839. Epub 2018 Mar 21.

Helping EGFR inhibition to block cancer.

Warta R, Herold-Mende C.

Nat Neurosci, 2017 Jul 26;20(8):1035-1037. doi: 10.1038/nn.4605.

Proteomics-based identification of T cell target antigens in quiescent stem-like glioblastoma cells.

Rapp C, Warta R, Stamova S, Nowrouzi A, Geisenberger C, Gal Z, Roesch S, Dettling S, Juenger S, Bucur M, Jungk C, DaoTrong P, Ahmadi R, Sahm F, Reuss D, Fermi V, Herpel E, Eckstein V, Grabe N, Schramm C, Weigand MA, Debus J, von Deimling A, Unterberg A, Abdollahi A, Beckhove P, Herold-Mende C.

Acta Neuropathol, 2017 Aug;134(2):297-316. doi: 10.1007/s00401-017-1702-1. Epub 2017 Mar 22.

Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.

Jungk C, Mock A, Exner J, Geisenberger C, Warta R, Capper D, Abdollahi A, Friauf S, Lahrmann B, Grabe N, Beckhove P, von Deimling A, Unterberg A, Herold-Mende C.

BMC Med. 2016 Oct 26;14(1):170.

Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis.

Jungk C, Scherer M, Mock A, Capper D, Radbruch A, von Deimling A, Bendszus M, Herold-Mende C, Unterberg A.

J Neurooncol. 2016 Sep;129(2):319-28. doi: 10.1007/s11060-016-2177-y.

Combined Treatment of ATRA with Epigenetic Drugs Increases Aggressiveness of Glioma Xenografts.

Schmoch T, Gal Z, Mock A, Mossemann J, Lahrmann B, Grabe N, Schmezer P, Lasitschka F, Beckhove P, Unterberg A, Herold-Mende C.

Anticancer Res. 2016 Apr;36(4):1489-96.

Non-invasive glioblastoma immunoprofiling by printed peptide arrays.

Mock A, Herold-Mende C.

Oncoimmunology. 2015 Aug 12;5(2):e1069941. eCollection 2016 Feb.

LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.

Mock A, Geisenberger C, Orlik C, Warta R, Schwager C, Jungk C, Dutruel C, Geiselhart L, Weichenhan D, Zucknick M, Nied AK, Friauf S, Exner J, Capper D, Hartmann C, Lahrmann B, Grabe N, Debus J, von Deimling A, Popanda O, Plass C, Unterberg A, Abdollahi A, Schmezer P, Herold-Mende C.

Int J Cancer. 2016 Jul 15;139(2):424-32. doi: 10.1002/ijc.30069. Epub 2016 Mar 18.

New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs.

Sturm D, Orr BA, Toprak UH, Hovestadt V, Jones DT, Capper D, Sill M, Buchhalter I, Northcott PA, Leis I, Ryzhova M, Koelsche C, Pfaff E, Allen SJ, Balasubramanian G, Worst BC, Pajtler KW, Brabetz S, Johann PD, Sahm F, Reimand J, Mackay A, Carvalho DM, Remke M, Phillips JJ, Perry A, Cowdrey C, Drissi R, Fouladi M, Giangaspero F, Łastowska M, Grajkowska W, Scheurlen W, Pietsch T, Hagel C, Gojo J, Lötsch D, Berger W, Slavc I, Haberler C, Jouvet A, Holm S, Hofer S, Prinz M, Keohane C, Fried I, Mawrin C, Scheie D, Mobley BC, Schniederjan MJ, Santi M, Buccoliero AM, Dahiya S, Kramm CM, von Bueren AO, von Hoff K, Rutkowski S, Herold-Mende C, Frühwald MC, Milde T, Hasselblatt M, Wesseling P, Rößler J, Schüller U, Ebinger M, Schittenhelm J, Frank S, Grobholz R, Vajtai I, Hans V, Schneppenheim R, Zitterbart K, Collins VP, Aronica E, Varlet P, Puget S, Dufour C, Grill J, Figarella-Branger D, Wolter M, Schuhmann MU, Shalaby T, Grotzer M, van Meter T, Monoranu CM, Felsberg J, Reifenberger G, Snuderl M, Forrester LA, Koster J, Versteeg R, Volckmann R, van Sluis P, Wolf S, Mikkelsen T, Gajjar A, Aldape K, Moore AS, Taylor MD, Jones C, Jabado N, Karajannis MA, Eils R, Schlesner M, Lichter P, von Deimling A, Pfister SM, Ellison DW, Korshunov A, Kool M.

Cell. 2016 Feb 25;164(5):1060-72. doi: 10.1016/j.cell.2016.01.015.

Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as prognostic biomarkers independent of WHO grade.

Schmidt M, Mock A, Jungk C, Sahm F, Ull AT, Warta R, Lamszus K, Gousias K, Ketter R, Roesch S, Rapp C, Schefzyk S, Urbschat S, Lahrmann B, Kessler AF, Löhr M, Senft C, Grabe N, Reuss D, Beckhove P, Westphal M, von Deimling A, Unterberg A, Simon M, Herold-Mende C.

Oncotarget. 2016 Mar 22;7(12):14551-68. doi: 10.18632/oncotarget.7396.

Chemotherapy with BCNU in recurrent glioma: Analysis of clinical outcome and side effects in chemotherapy-naïve patients.

Jungk C, Chatziaslanidou D, Ahmadi R, Capper D, Bermejo JL, Exner J, von Deimling A, Herold-Mende C, Unterberg A.

BMC Cancer. 2016 Feb 10;16:81. doi: 10.1186/s12885-016-2131-6.

Prognostic factors and long-term survival in surgically treated brain metastases from non-small cell lung cancer.

Enders F, Geisenberger C, Jungk C, Bermejo JL, Warta R, von Deimling A, Herold-Mende C, Unterberg A.

Clin Neurol Neurosurg. 2016 Mar;142:72-80. doi: 10.1016/j.clineuro.2016.01.011. Epub 2016 Jan 14.

TERT Promoter Mutations and Risk of Recurrence in Meningioma.

Sahm F, Schrimpf D, Olar A, Koelsche C, Reuss D, Bissel J, Kratz A, Capper D, Schefzyk S, Hielscher T, Wang Q, Sulman EP, Adeberg S, Koch A, Okuducu AF, Brehmer S, Schittenhelm J, Becker A, Brokinkel B, Schmidt M, Ull T, Gousias K, Kessler AF, Lamszus K, Debus J, Mawrin C, Kim YJ, Simon M, Ketter R, Paulus W, Aldape KD, Herold-Mende C, von Deimling A.

J Natl Cancer Inst. 2015 Dec 13;108(5). pii: djv377. doi: 10.1093/jnci/djv377. Print 2016 May.

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group.

Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, Wick W, Ellingson BM, Hashimoto N, Pollack IF, Brandes AA, Franceschi E, Herold-Mende C, Nayak L, Panigrahy A, Pope WB, Prins R, Sampson JH, Wen PY, Reardon DA.

Lancet Oncol. 2015 Nov;16(15):e534-42. doi: 10.1016/S1470-2045(15)00088-1. Review.

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Cancer Genome Atlas Research Network, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, [...] Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG Jr, Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, Mclendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J.

N Engl J Med. 2015 Jun 25;372(26):2481-98. doi: 10.1056/NEJMoa1402121. Epub 2015 Jun 10.

Endothelial Cells Derived from Non-malignant Tissues Are of Limited Value as Models for Brain Tumor Vasculature.

Lohr J, Mock A, Beckhove P, Herold-Mende C.

Anticancer Res. 2015 May;35(5):2681-90.

Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients.

Mock A, Warta R, Geisenberger C, Bischoff R, Schulte A, Lamszus K, Stadler V, Felgenhauer T, Schichor C, Schwartz C, Matschke J, Jungk C, Ahmadi R, Sahm F, Capper D, Glass R, Tonn JC, Westphal M, von Deimling A, Unterberg A, Bermejo JL, Herold-Mende C.

Oncotarget. 2015 May 30;6(15):13579-90.

Retinoid resistance and multifaceted impairment of retinoic acid synthesis in glioblastoma.

Campos B, Weisang S, Osswald F, Ali R, Sedlmeier G, Bageritz J, Mallm JP, Hartmann C, von Deimling A, Popanda O, Goidts V, Plass C, Unterberg A, Schmezer P, Burhenne J, Herold-Mende C.

Glia. 2015 Oct;63(10):1850-9. doi: 10.1002/glia.22849. Epub 2015 May 6.

Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain.

Geisenberger C, Mock A, Warta R, Rapp C, Schwager C, Korshunov A, Nied AK, Capper D, Brors B, Jungk C, Jones D, Collins VP, Ichimura K, Bäcklund LM, Schnabel E, Mittelbron M, Lahrmann B, Zheng S, Verhaak RG, Grabe N, Pfister SM, Hartmann C, von Deimling A, Debus J, Unterberg A, Abdollahi A, Herold-Mende C.

Acta Neuropathol. 2015 Sep;130(3):419-34. doi: 10.1007/s00401-015-1427-y. Epub 2015 May 1.

Molekulare Neuroonkologie